Risk for osteoporotic fractures in patients with atrial fibrillation using different oral anticoagulants

Table 3 Risk of major fracture comparing inverse probability of treatment weighted users of NOACs

NOAC vs. NOAC	All patients		Male		Female		P value for interaction^a
	Weighted HR (95% CI)	P value	Weighted HR (95% CI)	P value	Weighted HR (95% CI)	P value	P value for interaction^a
Apixaban versus Dabigatran	1.02 (0.84–1.25)	0.847	0.95 (0.74–1.23)	0.689	1.06 (0.82–1.37)	0.665	0.646
Rivaroxaban versus dabigatran	1.15 (1.02–1.31)	0.023	0.96 (0.77–1.20)	0.716	1.22 (1.05–1.42)	0.010	0.088
Rivaroxaban versus apixaban	1.13 (0.93–1.38)	0.227	1.01 (0.78–1.31)	0.935	1.15 (0.89–1.50)	0.294	0.544

CI confidence interval, HR hazard ratio, NOAC non-vitamin K antagonist oral anticoagulant
^aP value for interaction between treatment effect and sex

ISSN: 2466-1171